

Local Coverage Article: Billing and Coding: Mometasone Furoate Sinus Implant (Sinuva, Propel family of Implants) (A58141)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Noridian Healthcare Solutions, LLC	A and B MAC	01111 - MAC A	J - E	California - Entire State
Noridian Healthcare Solutions, LLC	A and B MAC	01112 - MAC B	J - E	California - Northern
Noridian Healthcare Solutions, LLC	A and B MAC	01182 - MAC B	J - E	California - Southern
Noridian Healthcare Solutions, LLC	A and B MAC	01211 - MAC A	J - E	American Samoa Guam Hawaii Northern Mariana Islands
Noridian Healthcare Solutions, LLC	A and B MAC	01212 - MAC B	J - E	American Samoa Guam Hawaii Northern Mariana Islands
Noridian Healthcare Solutions, LLC	A and B MAC	01311 - MAC A	J - E	Nevada
Noridian Healthcare Solutions, LLC	A and B MAC	01312 - MAC B	J - E	Nevada
Noridian Healthcare Solutions, LLC	A and B MAC	01911 - MAC A	J - E	American Samoa California - Entire State Guam Hawaii Nevada Northern Mariana Islands

Article Information

General Information

Article ID

A58141

Original Effective Date

04/20/2020

Article Title

Billing and Coding: Mometasone Furoate Sinus Implant
(Sinuva, Propel family of Implants)

Revision Effective Date

07/01/2020

Article Type

Billing and Coding

Revision Ending Date

N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Retirement Date

N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2013 - 2020, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association.

To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@aha.org.

CMS National Coverage Policy

N/A

Article Guidance

Article Text:

Noridian has received numerous billing and coding queries regarding J7401, (Mometasone Furoate Sinus Implant). This code became effective 10/1/2019. Two brand name products currently on the market are the Sinuva 1350 mcg. implant and the Propel family of sinus implants. Each brand name product has been approved by the Food and Drug Administration (FDA) for its own set of clinical indications and dosages.

This article is not a coverage determination, but rather guidance on the appropriate billing and coding when utilizing any of these products.

As a reminder, the Internet Only Manual (IOM), Medicare Benefit Policy Manual (Pub. 100-02), Chapter 15, Section 50.4.1 Approved Use of Drug states, *"Use of the drug or biological must be safe and effective and otherwise reasonable and necessary. Drugs or biologicals approved for marketing by the Food and Drug Administration (FDA) are considered safe and effective for purposes of this requirement when used for indications specified on the labeling. Therefore, the program may pay for the use of an FDA approved drug or biological, if:*

- *it was injected on or after the date of the FDA's approval;*
- *it is reasonable and necessary for the individual patient and,*
- *all other applicable coverage requirements are met."*

When billing any of the above-mentioned implants, when provided in accordance with the FDA indications, and in the manner specified by the FDA, use J-code J7401 along with the appropriate billable units.

It is understood that some type of endoscopic sinus procedure will be required for insertion of the implant. Unless bundled with a separate endoscopic sinus procedure (i.e., 31231-31298), should the need arise to bill solely for the endoscopic implantation of J7401, CPT® code 31299 (Unlisted procedure, accessory sinuses) must be utilized.

For all other non-FDA indicated uses of the mometasone furoate sinus implant, J3490 must be used along with the appropriate billable units. Noridian will review these claims on a case-by-case basis.

Regardless, if billing J7401 or J3490, providers must:

1. Include the respective National Drug Code (NDC) and brand name in the following comment/narrative fields:

Loop 2400 or SV101-7 for the 5010A1 837P if billing electronically, or

Item 19 of the CMS-1500 claim form if qualified to bill by paper.

2. For bilateral placement of sinus implants, must bill each respective side on a separate claim line along with -RT or -LT modifier.
3. For bilateral placement of sinus implants in more than one sinus cavity, (example, maxillary and frontal sinuses), along with -RT and -LT modifier, must additionally bill modifier -76 on each separate claim line for the additional sinuses.
 - a. Example Propel Contour:
 - i. Placement of sinus implants in bilateral maxillary sinuses – bill each implant on separate claim line along with -RT or -LT modifier
 - ii. Additionally, placement of sinus implants in bilateral frontal sinuses – bill each implant on separate claim line along with -RT and -76 modifiers or -LT and -76 modifiers.

***It should be noted, if the endoscopic procedure is performed in a facility such as an Ambulatory Surgical Center, J7401 is assigned status indicator N in the Outpatient Prospective Payment System (OPPS); therefore, no separate payment will be made; and the steroid implant is bundled into the procedure payment itself.

*** Effective July 1, 2020, Mometasone Furoate, brand name Sinuva may now be billed with the new C Code (C9122) if paid under OPPS.

Coding Information

CPT/HCPCS Codes

Group 1 Paragraph:

N/A

Group 1 Codes:

CODE	DESCRIPTION
31299	UNLISTED PROCEDURE, ACCESSORY SINUSES
C9122	MOMETASONE FUROATE SINUS IMPLANT, 10 MICROGRAMS (SINUVA)
J3490	UNCLASSIFIED DRUGS
J7401	MOMETASONE FUROATE SINUS IMPLANT, 10 MICROGRAMS

CPT/HCPCS Modifiers

N/A

ICD-10 Codes that Support Medical Necessity

N/A

ICD-10 Codes that DO NOT Support Medical Necessity

N/A

Additional ICD-10 Information

N/A

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

Other Coding Information

N/A

Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION
07/01/2020	R2	Revised to further clarify how to bill and code sinus implant when used bilaterally as well as in more than one set of sinus cavities.
07/01/2020	R1	Article updated to add HCPCS code C9122 for OPPS, and correct formatting and grammar.

Associated Documents

Related Local Coverage Document(s)

N/A

Related National Coverage Document(s)

N/A

Statutory Requirements URL(s)

N/A

Rules and Regulations URL(s)

N/A

CMS Manual Explanations URL(s)

N/A

Other URL(s)

N/A

Public Version(s)

Updated on 10/30/2020 with effective dates 07/01/2020 - N/A

Updated on 08/26/2020 with effective dates 07/01/2020 - N/A

Updated on 05/01/2020 with effective dates 04/20/2020 - N/A

Keywords

- Sinus
- Implant
- Sinuva
- Propel
- Mometasone Furoate